MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

MPC-004 for the Treatment of an Acute Gout Flare

Phase 3
Completed
Conditions
Gout
Interventions
Drug: High Dose Colchicine (4.8 mg total dose)
Drug: Low Dose Colchicine (1.8mg total dose)
Other: Placebo Control
First Posted Date
2007-07-25
Last Posted Date
2012-11-01
Lead Sponsor
Takeda
Target Recruit Count
185
Registration Number
NCT00506883
Locations
🇺🇸

Medical Research Trust, Lake Worth, Florida, United States

🇺🇸

Bond Clinic, Winter Haven, Florida, United States

🇺🇸

Jacksonville Center for Clinical Research, Jacksonville, Florida, United States

and more 42 locations

Safety Study of Pioglitazone Compared To Glyburide on Liver Function

Phase 4
Completed
Conditions
Diabetes Mellitus
Liver
Interventions
Drug: Glyburide
Drug: Pioglitazone
First Posted Date
2007-06-29
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
2120
Registration Number
NCT00494312

Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers

Phase 4
Completed
Conditions
Circadian Dysregulation
Interventions
Drug: Ramelteon
Drug: Placebo
First Posted Date
2007-06-27
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
110
Registration Number
NCT00492011

Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia

Phase 4
Completed
Conditions
Chronic Insomnia
Interventions
Drug: Ramelteon and zolpidem
Drug: Placebo and zolpidem
First Posted Date
2007-06-27
Last Posted Date
2010-07-20
Lead Sponsor
Takeda
Target Recruit Count
135
Registration Number
NCT00492232

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

First Posted Date
2007-06-19
Last Posted Date
2012-05-24
Lead Sponsor
Takeda
Target Recruit Count
2130
Registration Number
NCT00487994

Adherence to PTH(1-84) Treatment (FP-002-IM)

Completed
Conditions
Clinical Use of PTH(1-84)
Interventions
Drug: Parathyroid Hormone (PTH) (1-84)
First Posted Date
2007-05-25
Last Posted Date
2014-05-28
Lead Sponsor
Takeda
Target Recruit Count
1179
Registration Number
NCT00478569
Locations
🇩🇰

Nycomed, Roskilde, Denmark

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

Phase 2
Completed
Conditions
Esophagitis
Interventions
Drug: Lansoprazole
Drug: Ilaprazole
First Posted Date
2007-05-09
Last Posted Date
2012-02-02
Lead Sponsor
Takeda
Target Recruit Count
831
Registration Number
NCT00471094

The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)

Phase 4
Terminated
Conditions
Gastroesophageal Reflux Disease
Non-erosive Reflux Disease
Interventions
Drug: Pantoprazole
First Posted Date
2007-03-21
Last Posted Date
2012-05-07
Lead Sponsor
Takeda
Target Recruit Count
40
Registration Number
NCT00449813
Locations
🇨🇭

Altana Pharma/Nycomed, Zürich, Switzerland

Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.

Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Pioglitazone and sulphonylurea
Drug: Pioglitazone and metformin
First Posted Date
2007-03-20
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
326
Registration Number
NCT00449553

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Phase 3
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Alogliptin
Drug: Pioglitazone
Drug: Metformin
Drug: Placebo
First Posted Date
2007-02-07
Last Posted Date
2013-04-04
Lead Sponsor
Takeda
Target Recruit Count
803
Registration Number
NCT00432276
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy